Sex | Male 35 | Status of complications | |
Female 10 | |||
mean ± SD | |||
Age(years) | 61.1 ± 12.0 | Retinopathy | 13.3% |
Weight(kg) | 66.5 ± 12.9 | Nephropathy | 9.8% |
BMI(kg/m2) | 24.7 ± 4.0 | Neuropathy | 26.7% |
HbA1c(%) | 7.4 ± 1.0 | IHD | 20.0% |
Non-fasting Glu(mg/dL) | 164.6 ± 39.2 | CI | 13.3% |
LDL-C(mg/dL) | 102.9 ± 19.7 | ASO | 0.0% |
HDL-C(mg/dL) | 60.7 ± 19.3 | Status of antihypertensive drug administration | |
Non-fasting TG(mg/dL) | 137.4 ± 93.9 | ARB | 31.1% |
SBP(mmHg) | 125.2 ± 12.8 | CCB | 31.1% |
DBP(mmHg) | 67.6 ± 9.0 | Status of anti-dyslipidemiadrug administration | |
Apo B(mg/dL) | 91.0 ± 16.4 | Statin | 60.0% |
Apo A-I(mg/dL) | 153.1 ± 27.4 | Fibrate | 6.6% |
Serum CPR(ng/mL) | 4.1 ± 2.1 | Ezetimibe | 8.9% |